Envudeucitinib for Active Systemic Lupus Erythematosus

Envudeucitinib for Active Systemic Lupus Erythematosus
41%30%19%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 27 • YES 29.9%
Alumis Inc ($ALMS)
No stock close$22.52$21.74$20.96May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 18 • ALMS $21.15May 19 • ALMS $21.53May 20 • ALMS $22.04May 21 • ALMS $22.17May 22 • ALMS $22.02May 26 • ALMS $22.33May 27 • ALMS $21.50

Will this trial show a positive result on proportion of patients with BICLA lupus disease-activity response at Week 48?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle

Matched news6 items

All news
ALMS

Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) Quality‑of‑life improvements and itch relief emerged ahead of PASI 90 skin clearance, and clear or almost clear scalp psoriasis emerged

Trial Results • Phase 3Matched envudeucitinib, active, systemic, lupus, erythematosus
ALMS

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

– Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis – – Approximately 65% of patients achieved PASI 90 and more than 40% achieved PASI 100 at Week 24, on average – – Envudeucitinib demonstrated a

Trial Results • Phase 3Matched envudeucitinib, active, systemic, lupus, erythematosus
ALMS

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

– Phase 3 data presentation highlighting results from the ONWARD1 and ONWARD2 clinical trials of envudeucitinib – – Phase 2 STRIDE e-poster presentation to describe disease biomarker activity of envudeucitinib – – Alumis to host investor webcast on Sunday, March 29, 2026, at 5:00 pm MDT / 7:00 pm

Results Call • Phase 3Matched envudeucitinib, active, systemic, lupus, erythematosus
ALMS

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

– Conference Call and Webcast to be held Tuesday, January 6, 2026, at 8:00 a.m. ET – SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases,

Results Call • Phase 3Matched envudeucitinib, systemic, lupus, erythematosus
ALMS

Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements

– Late - breaking oral presentation of Phase 3 envudeucitinib data in moderate - to - severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms – – Data showed robust

Presentation / Abstract • Phase 3oral presentation Thu, May 14, 2026Matched envudeucitinib, systemic, lupus, erythematosus
ALMS

Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements

– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis (PsO) – – Plan to submit NDA for envudeucitinib in PsO in 2H 2026 – – Potentially pivotal

Presentation / Abstract • Phase 3Matched envudeucitinib, systemic, lupus, erythematosus